Compare Gilead Sciences, Inc. (GILD) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.21 (market cap $4.35B). The key difference: Gilead Sciences, Inc. is far larger — about 41.9× State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days on average.
| GILD | SJNK | |
|---|---|---|
Market Cap | $182.40B | $4.35B |
Volume | 4,469,821 | 3,211,044 |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $25.57 |
52-Week Low | $117.18 | $24.13 |
Typical Hold Time | 111 Days | 41 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
SJNK, the SPDR Bloomberg Short Term High Yield Bond ETF, trades at $24.18 with a slight 24-hour decline of 0.08%. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF has maintained consistent dividend payments recently, with three distributions of $0.14-$0.15 scheduled for late 2026. Institutional activity shows mixed sentiment with Cetera Investment Advisers and Balefire LLC reducing positions in recent quarters.
The ETF faces headwinds from the current bearish technical setup while offering yield advantages over Treasury securities. Key risks include interest rate sensitivity and high-yield bond market volatility. Investors should weigh the attractive dividend yield against the technical weakness and institutional selling pressure when considering position sizing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
